| 2.19 0 (0%) | 04-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.56 | 1-year : | 2.56 |
| Resists | First : | 2.19 | Second : | 2.2 |
| Pivot price | 2.19 | |||
| Supports | First : | 2.19 | Second : | 1.82 |
| MAs | MA(5) : | 2.19 | MA(20) : | 2.19 |
| MA(100) : | 2.19 | MA(250) : | 2.06  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 61.8 | |||
| 52-week | High : | 2.75 | Low : | 1.39 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ETTX ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 113 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.21 - 2.22 | 2.22 - 2.22 |
| Low: | 2.16 - 2.17 | 2.17 - 2.19 |
| Close: | 2.17 - 2.19 | 2.19 - 2.21 |
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.
Sun, 14 Apr 2024
Entasis' (ETTX) Phase III Study on Infection Drug Meets Goal - Yahoo Movies UK
Mon, 18 Jul 2022
Hedge Fund and Insider Trading News: D.E. Shaw, Elliott Management, Millennium Management, Marshall Wace LLP ... - Insider Monkey
Wed, 25 May 2022
Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva - Yahoo Singapore News
Mon, 23 May 2022
Innoviva to Acquire Entasis Therapeutics - GlobeNewswire
Wed, 02 Feb 2022
Entasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc. - GlobeNewswire
Mon, 10 Jan 2022
Entasis Therapeutics to Participate in H.C. Wainwright - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 66.3 (%) |
| Held by Institutions | 10.4 (%) |
| Shares Short | 72 (K) |
| Shares Short P.Month | 105 (K) |
| EPS | -1.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -71.7 % |
| Return on Equity (ttm) | -169.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -47 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -1.96 |
| PEG Ratio | -0.1 |
| Price to Book value | 6.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|